462 related articles for article (PubMed ID: 33978991)
1. RHEDAR study: Determination of the risk of gastrointestinal hemorrhage in treatment with dabigatran, acenocoumarol and rivaroxaban.
Agudo-Fernández S; Castaño Milla C; González Blanco A; Olmos Jerez JA; Calvo Morillas I; Sancho Del Val L
J Gastroenterol Hepatol; 2021 Oct; 36(10):2794-2802. PubMed ID: 33978991
[TBL] [Abstract][Full Text] [Related]
2. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
Lip GYH; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Deitelzweig S
JAMA Netw Open; 2021 Aug; 4(8):e2120064. PubMed ID: 34398204
[TBL] [Abstract][Full Text] [Related]
3. Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study.
Bouillon K; Bertrand M; Maura G; Blotière PO; Ricordeau P; Zureik M
Lancet Haematol; 2015 Apr; 2(4):e150-9. PubMed ID: 26687957
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
6. Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding.
Ray WA; Chung CP; Murray KT; Smalley WE; Daugherty JR; Dupont WD; Stein CM
JAMA; 2018 Dec; 320(21):2221-2230. PubMed ID: 30512099
[TBL] [Abstract][Full Text] [Related]
7. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
[TBL] [Abstract][Full Text] [Related]
8. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
12. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation.
Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303
[TBL] [Abstract][Full Text] [Related]
14. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
[TBL] [Abstract][Full Text] [Related]
15. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials.
Loffredo L; Perri L; Violi F
Dig Liver Dis; 2015 May; 47(5):429-31. PubMed ID: 25732432
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
17. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Chang HY; Zhou M; Tang W; Alexander GC; Singh S
BMJ; 2015 Apr; 350():h1585. PubMed ID: 25911526
[TBL] [Abstract][Full Text] [Related]
18. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]